Certara, Inc. (NASDAQ:CERT) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 70.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 57,014 shares of the company's stock after selling 132,856 shares during the period. Janus Henderson Group PLC's holdings in Certara were worth $667,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. acquired a new position in Certara in the 2nd quarter valued at about $26,000. Innealta Capital LLC purchased a new stake in Certara in the 2nd quarter valued at approximately $36,000. KBC Group NV boosted its holdings in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after purchasing an additional 1,584 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Certara in the 2nd quarter valued at approximately $152,000. Finally, Algert Global LLC purchased a new stake in Certara in the 2nd quarter valued at approximately $156,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Price Performance

Shares of NASDAQ:CERT traded down $0.24 during trading on Friday, hitting $11.47. 1,828,939 shares of the stock were exchanged, compared to its average volume of 837,594. The company has a fifty day moving average price of $10.84 and a two-hundred day moving average price of $12.63. The company has a market cap of $1.85 billion, a PE ratio of -57.35, a P/E/G ratio of 5.86 and a beta of 1.53. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12-month low of $9.41 and a 12-month high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company's quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.06 EPS. On average, analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Insider Buying and Selling

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.39% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CERT shares. Robert W. Baird lowered their price objective on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, November 5th. UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price objective on the stock in a report on Friday, September 27th. Finally, Barclays lowered their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, November 7th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.